Bone Mass Measurements — CPB 0134 | AETNA Coverage Update

Aetna modified CPB 0134 governing bone mass measurement coverage, effective September 26, 2025. Here's what billing teams need to know before claims go out the door.

Aetna, a CVS Health company, updated its bone mass measurement coverage policy under CPB 0134 Aetna system. The change affects 29 CPT codes and seven HCPCS codes — including 77080, 77085, 77086, 77089, and the trabecular bone score codes 77089–77092. If your practice bills DXA scans, vertebral fracture assessments, or quantitative CT bone density studies for Aetna members, this policy sets the rules your claims will be measured against starting September 26, 2025.

---

Quick Reference: Aetna CPB 0134 Bone Mass Measurement Policy 2025

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Bone Mass Measurements – CPB 0134
Policy Code	CPB 0134
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Radiology, Endocrinology, Rheumatology, Oncology, Primary Care, OB/GYN, Neurology
Key Action	Audit your bone density charge capture against the 15 covered indications and update medical necessity documentation before September 26, 2025

---

Aetna Bone Mass Measurement Coverage Criteria and Medical Necessity Requirements 2025

The Aetna bone mass measurement coverage policy under CPB 0134 recognizes 15 separate indications for medical necessity. Your documentation needs to match one of them. No indication, no coverage — it's that simple.

Here's the full list. A member qualifies if they meet any one of the following:

Three of these indications — screening for men over 50 with risk factors, screening for men over 70, and screening for peri/post-menopausal women — require a preventive services benefit. Verify the member's benefit structure before you bill. A claim denial on a missing preventive benefit is entirely preventable.

The policy establishes DXA (CPT 77080, 77085) as the standard for monitoring drug therapy response. Other methods like quantitative CT (CPT 77078) and ultrasound bone density (CPT 76977) have specific restrictions. Know which method you're using and whether it fits the indication.

The standard repeat interval is once every two years. Reimbursement for more frequent studies requires one of three specific circumstances — and those circumstances are not interchangeable with clinical judgment alone.

---

Aetna Bone Mass Measurement Exclusions and Non-Covered Indications

Several techniques and expanded scan protocols are restricted under this coverage policy.

Monitoring osteoporosis drug therapy with QCT: CPT 77078 is not covered for monitoring osteoporosis treatment response. Only DXA applies for that indication.

Ultrasound bone density (CPT 76977): Listed in the policy but flagged as not covered for monitoring osteoporosis treatment response. Check the indication carefully before billing 76977.

Cone beam CT (CPT 70486, 70487, 70488): Not covered for osteoporosis screening. These maxillofacial CT codes appear in the policy specifically to draw that line.

Simultaneous axial and appendicular scans: Only covered in three narrow circumstances — confirmatory baseline after a technique switch, appendicular scan when axial artifacts interfere, or uncorrected primary hyperparathyroidism. Billing both axial and appendicular outside these three scenarios will not hold up to audit.

Repeat bone mass measurement: More frequent than every two years is only supported for glucocorticoid or anticonvulsant therapy monitoring (>3 months), confirmatory baseline when switching techniques, or uncorrected primary hyperparathyroidism monitoring. Everything else — including clinical concern, patient request, or provider preference — is not a supported indication under this policy.

Advanced Category III codes (0554T–0557T, 0743T, 0749T, 0750T, 0691T, 0815T): These newer finite element analysis and REMS codes appear in the policy but sit outside the standard covered code group. If you're billing these, pull the policy language carefully and confirm coverage with Aetna directly before submission. Talk to your compliance officer if your volume on these codes is significant.

---

Coverage Indications at a Glance

---

Aetna Bone Density Billing Guidelines and Action Items 2025

1. Audit your documentation before September 26, 2025.
Pull any open or pending bone density orders and confirm each maps to one of the 15 covered indications. If the chart note says "osteoporosis screening" without specifying sex, age, menopausal status, or a qualifying condition, the claim is at risk.

2. Verify preventive benefits before billing screening DXAs.
Men over 50 with risk factors, men over 70, and peri/post-menopausal women — all three screening categories require an active preventive services benefit. Confirm eligibility before the scan, not after the denial.

3. Update charge capture for TBS and VFA codes.
Trabecular bone score codes (77089, 77090, 77091, 77092) and vertebral fracture assessment (77086) are covered under this policy — but only when the member already meets criteria for bone mass measurement. Don't bill these standalone. Your charge capture workflow should tie them to a qualifying DXA order with documentation of the primary indication.

4. Stop billing simultaneous axial and appendicular outside the three covered scenarios.
If your practice routinely orders both axial and appendicular scans for new patients, that practice needs a second look. The only supported scenarios are a technique-switch baseline, axial artifact interference, and uncorrected primary hyperparathyroidism. Everything else is a denial waiting to happen.

5. Flag glucocorticoid and anticonvulsant therapy patients for more frequent monitoring.
These two medication classes are the clearest path to billing bone density more often than every two years. Your EHR should flag patients on prednisone ≥5 mg/day for >3 months and patients on phenytoin or phenobarbital for repeat DXA at appropriate intervals. Build that logic now so you're not chasing documentation retroactively.

6. Map androgen deprivation therapy drugs to the correct HCPCS and qualifying diagnosis.
If you're billing leuprolide (J1950, J9217, J9218, J9219) or goserelin (J9202), the male patient receiving those drugs qualifies for bone density monitoring. That connection should be explicit in your billing documentation — not assumed.

7. Review advanced Category III code billing with your compliance officer.
Codes like 0554T–0557T (finite element analysis), 0743T, 0749T, 0750T, and 0815T (REMS) appear in this policy but don't sit cleanly in the covered code group. If you're billing these for Aetna members, get a clear answer from Aetna on coverage before the effective date of September 26, 2025. Your compliance officer should be part of that conversation.

---

CPT, HCPCS, and ICD-10 Codes for Bone Mass Measurement Under CPB 0134

Covered CPT Codes (When Selection Criteria Are Met)

Category III / Advanced Technology CPT Codes

Not Covered for Osteoporosis Screening — CPT Codes

Code	Description	Reason Copy
70486	Computed tomography, maxillofacial area; without contrast	Not covered for osteoporosis screening
70487	Computed tomography, maxillofacial area; with contrast	Not covered for cone beam CT
70488	Computed tomography, maxillofacial area; without then with contrast	Not covered for cone beam CT

Related CT Codes (Other)

Covered HCPCS Codes

Code	Description Copy
G0130	Single energy x-ray absorptiometry (SEXA) bone density study, appendicular skeleton

Related Drug HCPCS Codes (Qualifying Medications)

Key ICD-10-CM Diagnosis Codes

The full policy lists 207 ICD-10-CM codes. The complete code set — covering hyperthyroidism variants, osteoporosis, fractures, hypogonadism, Turner syndrome, and related diagnoses — is available in the full policy document at CPB 0134 on PayerPolicy.

---